Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ.

J Clin Oncol. 2009 Nov 20;27(33):5506-12. doi: 10.1200/JCO.2009.22.1309.

2.

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR; Cancer Leukemia Group B..

Ann Oncol. 2004 Mar;15(3):410-8. Review.

PMID:
14998842
3.

Gemcitabine-based combination treatment of pancreatic cancer.

Heinemann V.

Semin Oncol. 2002 Feb;29(1 Suppl 3):25-35. Review.

PMID:
11894005
4.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.

Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review.

PMID:
12642688
5.

Docetaxel followed by gemcitabine and irinotecan in solid tumors.

Rocha Lima CM, Urbanic JJ, Sherman CA, Brescia FJ, Green MR.

Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):37-45. Review.

6.

Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.

Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR.

Semin Oncol. 2001 Jun;28(3 Suppl 10):34-43. Review.

PMID:
11510032
7.

Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

Walker EJ, Ko AH.

World J Gastroenterol. 2014 Mar 7;20(9):2224-36. doi: 10.3748/wjg.v20.i9.2224. Review.

8.

Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.

Sclafani F, Iyer R, Cunningham D, Starling N.

Crit Rev Oncol Hematol. 2015 Sep;95(3):318-36. doi: 10.1016/j.critrevonc.2015.03.008. Review.

PMID:
25921418
9.

Systemic therapies for pancreatic cancer--the role of pharmacogenetics.

Soo RA, Yong WP, Innocenti F.

Curr Drug Targets. 2012 Jun;13(6):811-28. Review.

10.

MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.

Carnevale J, Ko AH.

Future Oncol. 2016 Feb;12(4):453-64. doi: 10.2217/fon.15.333. Review.

PMID:
26685802
Items per page

Supplemental Content

Support Center